$ 10.07
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of BHVN is 21 and suggests 110% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only